EUCTR2008-003098-42-CZ进行中（未招募）1 期
A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria within 28 days prior to their first dose of Avonex® on Day 1 (Baseline Visit):
- •1.Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- •2.Male or female aged 18 to 60 years old, inclusive, at the time of informed consent.
- •3.Must have a diagnosis of relapsing MS, as defined by the revised McDonald Committee criteria.
- •4.Must have a screening EDSS score between 0 and 6.0, inclusive.
- •5.All male subjects and female subjects of child-bearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last study dose of Avonex®.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Unless otherwise specified, candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of enrollment on Day 1 (Baseline Visit):
- •Medical History
- •1.Primary progressive, secondary progressive, or progressive relapsing MS. These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapses, but are distinguished from relapsing-remitting subjects by the lack of clinically stable periods or clinical improvement.
- •2.History of severe allergic or anaphylactic reactions.
- •3.Known allergy to any component of the Avonex® formulation.
- •4.History of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric renal, or other major disease.
- •5.Subjects with a history of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
- •6.History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to Day 1.
- •7.History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Severe depression is defined as any episode of depression that requires hospitalization, or the initiation of antidepressant therapy, or an increase in the dose of an existing regimen of antidepressant therapy. NOTE: Subjects receiving ongoing antidepressant therapy are not excluded from the study unless the dose has been increased within the 3 months prior to Day 1.
- •8.Clinically significant abnormal ECG values as determined by the Investigator.
- •9.Known history of, or a positive test result for, human immunodeficiency virus (HIV).
- •10.Known history of, or positive test result for hepatitis C virus (test for hepatitis C virus antibody [HCV Ab]) or Hepatitis B virus (test for Hepatitis B Surface Antigen [HBsAg] and/or Hepatitis B Core Antibody [HBcAb]).
- •11.Abnormal screening blood tests exceeding any of the limits defined below:
- •Alanine transaminase/serum glutamate pyruvate transaminase (ALT/SGPT) greater than 2 times the upper limit of normal (>2xULN) or aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) >2xULN or bilirubin >1.5xULN
- •Total white blood cell count (WBC) <3700 cells/mm3
- •Platelet count <150,000 cells/mm3
- •Hemoglobin <10g/dL in female subjects; <11g/dL in male subjects
- •Serum creatinine >ULN
- •Prothrombin time (PT) or activated partial thromboplastin time (aPTT) >1.2 xULN
- •Treatment History
- •12.Any previous treatment with any interferon product.
- •13.History of hypersensitivity or intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, or aspirin that would preclude use of at least one of these during the study.
- •14.Treatment with other agents to treat MS symptoms or underlying disease 15.Prior treatment with any other investigational drug for MS, or any other condition, not listed above, unless approved by the Biogen Idec Medical Director.
- •Miscellaneous
- •16.Female subjects who are currently pregnant or breast feeding. Female subjects of child bearing potential who have a positive pregnancy test at either the Screening Visit or the Day 1 (Baseline) Visit may not be enrolled into
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple SclerosisEUCTR2014-000917-30-BEBiogen Idec Research Limited113
进行中（未招募）
不适用
Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple SclerosisMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-000917-30-DKBiogen Idec Research Limited113
进行中（未招募）
不适用
Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple SclerosisMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-000917-30-ITBiogen Idec Research Limited113
进行中（未招募）
1 期
Immunogenicity and Safety Study of Natalizumab (BG00002) administered to Participants with Relapsing Multiple SclerosisMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-000917-30-DEBiogen Idec Research Limited113
已完成
不适用
A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO´s Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)Primary open-angle glaucomaPER-168-08OPKO Health Inc.,